# Normunity

> Normunity is a clinical-stage biotech building a new class of cancer drugs it calls 'immune normalizers' - antibodies and T cell engagers that target previously hidden mechanisms tumors use to evade the immune system. Founded on the science of Yale immunologist Lieping Chen and led by drug-development veteran Rachel Humphrey, the company runs research at Yale's West Campus in West Haven, Connecticut, and dosed its first patient in 2025.

- **Founded:** 2021
- **Headquarters:** Boston, Massachusetts, United States (research in West Haven, Connecticut)
- **Founders:** Rachel W. Humphrey (Founding President & CEO), Lieping Chen (Scientific Founder)
- **Team size:** ~22 employees
- **Products:** Immune Normalizers, NRM-823, Discovery platform, Pipeline modalities
- **Notable:** Launched in 2022 with $65M Series A out of the lab of PD-1/PD-L1 pioneer Lieping Chen, Raised a $75M Series B in January 2025 with Regeneron, Pfizer, and Sanofi venture arms participating, Advanced lead program NRM-823 from discovery to the clinic in roughly three years

## Products & services

- **Immune Normalizers** — A new class of biologic therapies targeting previously undiscovered mechanisms tumors use to disrupt normal immune function, aiming to restore - not over-stimulate - the body's own anti-cancer immunity.
- **NRM-823** — Lead program: a first-in-class T cell engager that binds a novel tumor-specific target expressed across multiple solid tumors but absent in normal tissue. Entered Phase 1 (NCT07182149) with first patient dosed November 2025.
- **Discovery platform** — Proprietary platforms that interrogate human cancer and immune-cell interactions in human cells and tissues, developed alongside the Lieping Chen lab at Yale, to find new targets and validate them.
- **Pipeline modalities** — Therapeutic antibodies, bispecific antibodies, payload-carrying biologics, antibody-drug conjugates, and radiotheranostics built against newly discovered tumor-specific targets.

## Achievements

- Launched in 2022 with $65M Series A out of the lab of PD-1/PD-L1 pioneer Lieping Chen
- Raised a $75M Series B in January 2025 with Regeneron, Pfizer, and Sanofi venture arms participating
- Advanced lead program NRM-823 from discovery to the clinic in roughly three years
- Dosed first patient in Phase 1 trial of NRM-823 in November 2025
- Total funding of ~$185 million across two rounds

## Latest updates

- **2025-11** — Announced first patient dosed in Phase 1 study (NCT07182149) of NRM-823, a first-in-class T cell engager for solid tumors.
- **2025-01** — Closed $75M Series B to push NRM-823 into the clinic and broaden the pipeline.
- **2022-10** — Launched publicly with $65M Series A financing.

## Links

- Website: https://normunity.com
- LinkedIn: https://www.linkedin.com/company/normunity
- Twitter/X: https://twitter.com/normunity

---

Profile page: https://yespress.io/normunity
Published by YesPress — https://yespress.io
Last updated: 2026-06-07